Decipher is now part of Veracyte!     Learn More
Decipher is now part of Veracyte!     Learn More
Skip to content
PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Present at 20th Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 2, 2021-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson , chairman and chief executive officer, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare
View HTML
Toggle Summary Veracyte Appoints Muna Bhanji to Its Board of Directors
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 22, 2021-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced the appointment of Muna Bhanji , R.Ph., a global senior healthcare executive, to its board of directors, effective immediately.
View HTML
Toggle Summary Veracyte Completes Acquisition of Decipher Biosciences
Further solidifies global leadership in differentiated, genomics-driven cancer diagnostics and expands TAM with presence in 7 of the 10 most common cancers Tina Nova , Ph.D., named Veracyte’s general manager, urologic cancers SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar.
View HTML
Toggle Summary Veracyte Commends New USPSTF Lung Cancer Screening Guidelines
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 10, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today commended the U.S. Preventive Services Task Force (USPSTF) for its new, revised recommendations that expand eligibility for lung cancer screening. The updated recommendations lower the age for
View HTML
Toggle Summary Veracyte to Present at 10th Annual SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 18, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson , chairman and chief executive officer, will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare
View HTML
Toggle Summary Veracyte Announces Fourth Quarter and Full-Year 2020 Financial Results
Fourth Quarter Revenue Increased 16% to $34.5 Million ; Volume Grew 14% to 13,130 Tests Decipher Acquisition to Expand Global Leadership in Cancer Genomic Diagnostics   While Accelerating Growth Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb.
View HTML
Toggle Summary Veracyte to Present at BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 11, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson , chairman and chief executive officer, will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health , Life
View HTML
Toggle Summary Veracyte to Release Fourth Quarter and Full-Year 2020 Financial Results on February 17, 2021
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 10, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its full financial results for the fourth quarter and full-year 2020 after the close of market on Wednesday, February 17 .
View HTML
Toggle Summary Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 9, 2021-- Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 8,547,297 shares of common stock, including 1,114,864 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a
View HTML
Toggle Summary Veracyte Announces Pricing of Upsized Public Offering of 7,432,433 Shares of Common Stock
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 4, 2021-- Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced the pricing of an underwritten public offering of 7,432,433 shares of its common stock at a public offering price of $74.00 per share.
View HTML